Sangamo Therapeutics (NASDAQ:SGMO) Rating Increased to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded Sangamo Therapeutics from a "sell" rating to a "hold" rating, indicating a potential shift in investor sentiment.
• Barclays has reduced its price target for Sangamo from $9.00 to $5.00 while still maintaining an "overweight" rating, showing mixed outlooks by analysts.
• Sangamo Therapeutics reported a loss in its latest earnings, missing revenue expectations and revealing a negative return on equity of 293.05%.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Saturday.

A number of other equities analysts also recently issued reports on the company. Barclays lowered their price target on Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 14th. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price target on shares of Sangamo Therapeutics in a report on Tuesday, June 24th. Four equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $4.50.

Sangamo Therapeutics Trading Down 5.8%

Shares of SGMO traded down $0.0341 during trading hours on Friday, hitting $0.5550. The company had a trading volume of 3,229,543 shares, compared to its average volume of 6,116,046. The company has a market capitalization of $167.45 million, a PE ratio of -1.91 and a beta of 1.18. Sangamo Therapeutics has a one year low of $0.4111 and a one year high of $3.1790. The company's fifty day moving average price is $0.52 and its two-hundred day moving average price is $0.70.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The business had revenue of $18.31 million for the quarter, compared to analyst estimates of $31.68 million. Sangamo Therapeutics had a negative net margin of 77.48% and a negative return on equity of 293.05%. Analysts forecast that Sangamo Therapeutics will post -0.46 earnings per share for the current year.

Institutional Trading of Sangamo Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SGMO. JPMorgan Chase & Co. lifted its holdings in Sangamo Therapeutics by 679.5% in the fourth quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 21,793 shares during the period. Captrust Financial Advisors bought a new stake in shares of Sangamo Therapeutics during the 4th quarter worth about $30,000. LPL Financial LLC increased its position in Sangamo Therapeutics by 113.5% during the 4th quarter. LPL Financial LLC now owns 31,031 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 16,498 shares in the last quarter. Lazard Asset Management LLC bought a new stake in Sangamo Therapeutics during the 4th quarter worth approximately $47,000. Finally, R Squared Ltd acquired a new position in shares of Sangamo Therapeutics during the 2nd quarter valued at $28,000. Institutional investors own 56.93% of the company's stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.